Molnupiravir speeds up recovery and eases long-term symptoms, but its minimal effect on hospitalizations raises questions about its broader impact on COVID-19 care. Study: Health outcomes 3 months and ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The antiviral reduced the risk for severe symptoms of ...
The antiviral drug molnupiravir (Lagevrio) slashed the risk of death from COVID-19 in half when given early to older adults. It also lowered all-cause deaths among older adults in the Czech Republic ...
Long COVID affects an estimated 65 million people worldwide and can damage the brain, heart, blood vessels, and immune system ...
In patients hospitalized with COVID-19, adding molnupiravir or nirmatrelvir-ritonavir to usual care was not associated with improved clinical outcomes, including 28-day mortality duration of hospital ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Antiviral therapy reduced incidence of long COVID-19 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback